What Is Bydureon?

1. How does Bydureon differ from Byetta?

Byetta and Bydureon contain the same peptide. The difference is the delivery. Exenatide on its own is cleared in hours, which is why Byetta is injected twice a day. Bydureon traps it in microspheres made of a biodegradable polymer, poly(D,L-lactide-co-glycolide) or PLGA; in BCise, the label lists 37.2 mg of that polymer per dose, suspended in a medium-chain triglyceride oil. After injection, the label describes an initial release of surface-bound drug, then a gradual release as the spheres absorb water and erode, with a peak around weeks 6 to 7 after a single dose.

On weekly dosing, the BCise label says blood levels rise gradually until about week 10, then hold at around 208 pg/mL. After the last dose, levels generally fall below the measurable limit of 20 pg/mL in about 10 weeks. That long tail matters for side effects, for anyone switching drugs and for a rare platelet reaction (section 7). How long GLP-1 drugs stay in your system puts those numbers next to other drugs in the class.

The label also warns that people moving from twice-daily exenatide to BCise may see blood glucose rise for about 2 to 4 weeks while weekly levels build.

2. What is the Bydureon dose?

The labeled regimen is simple: 2 mg injected under the skin of the abdomen, thigh or upper arm once every 7 days. There is no titration step. The label’s other rules:

• Changing the day. Allowed if the last dose was at least 3 days before the new day.
• Missed dose. Take it as soon as noticed if the next dose is at least 3 days away; if the next dose is due in 1 or 2 days, skip it.
• Preparation. BCise is taken out of the refrigerator 15 minutes before use, shaken hard for at least 15 seconds until evenly cloudy, and injected right away.
• With insulin. Separate injections, never mixed; the same body region is fine if the sites are not adjacent.
• Other exenatide. Any other exenatide product is stopped before starting.

These are the label’s instructions, given for reference, not advice.

3. What did the Bydureon trials show?

The weekly formulation was tested against Byetta first, then against oral drugs and newer GLP-1 drugs. HbA1c is a blood test that reflects average glucose over about three months.

In DURATION-1, 77% on the weekly form reached an HbA1c of 7.0% or less versus 61% on Byetta, with no increase in hypoglycemia. In the monotherapy trial, Bydureon was non-inferior to metformin and better than sitagliptin, but failed to show non-inferiority to pioglitazone.

Against newer GLP-1 drugs, it lost

In DURATION-6, weekly exenatide failed its pre-set test for non-inferiority to liraglutide, though it caused less nausea, diarrhea and vomiting. In SUSTAIN 3, semaglutide, the drug in Ozempic, was superior on both HbA1c and weight; 67% reached an HbA1c below 7.0% versus 40% on exenatide. The pattern is consistent: easier on the stomach, weaker on glucose and weight, and much more likely to irritate the skin.

Children

BCise is labeled for children 10 and older based on a 24-week trial of Bydureon in 82 people aged 10 to 17. HbA1c fell 0.25 points on Bydureon and rose 0.45 on placebo, a difference of 0.71 points (95% CI -1.42 to 0); weight changed little in either group.

4. What did EXSCEL find about the heart?

EXSCEL randomized 14,752 people with type 2 diabetes, 73.1% of whom already had cardiovascular disease, to weekly exenatide 2 mg or placebo on top of usual care. Median follow-up was 3.2 years. The label reports the results:

MACE is the composite of cardiovascular death, nonfatal heart attack and nonfatal stroke. Exenatide passed the safety test (P under 0.001 for non-inferiority) but missed superiority (P = 0.06). The trial paper adds that hospitalization for heart failure, acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma and serious adverse events did not differ significantly between groups.

That result is why Bydureon’s label never gained a cardiovascular risk-reduction indication; the label presents EXSCEL only as evidence that the drug did not increase risk. EXSCEL was a pragmatic trial, run like routine care, and the label notes a median treatment duration of 27.8 months against 38.7 months of follow-up, so many people were not on the drug for the whole trial. That may have diluted any effect, but it is a reason for caution in reading the result, not evidence of a hidden benefit.

5. Does Bydureon cause weight loss?

A little. Across the label’s trials, weight fell about 1.4 to 2.3 kg over 26 to 28 weeks, and 1.9 kg over 56 weeks in SUSTAIN 3. Bydureon was never tested or approved for weight management, and those numbers are small next to the drugs that are, such as Wegovy and Zepbound. No trial reviewed for this page measured body composition, so the split between fat and lean mass is unknown; GLP-1 drugs and muscle loss covers the general question.

6. What are Bydureon’s side effects?

The label’s safety data for BCise pool 526 adults from its two 28-week trials, with a mean exposure of 35 weeks:

Any injection-site reaction, including nodules, itching and bruising, occurred in 23.9%, and was more common in people with high antibody levels (27%) than in those with low or no antibodies (16%). Nausea mostly came early: nausea or vomiting affected 2% in the first week and 1% in the fourth. Overall, 3.9% stopped because of side effects. Mean heart rate rose by 2.4 beats per minute, and acute pancreatitis occurred in 0.4% of BCise trial patients.

The nausea rate is far lower than on Byetta, where 44% reported it in the add-on trials. The trade is the skin: the microspheres sit under the skin as they dissolve, and the label lists postmarketing reports of serious injection-site reactions, including abscess, cellulitis and tissue death, a few needing surgery.

7. What warnings and contraindications does the label carry?

Boxed warning. Extended-release exenatide caused thyroid C-cell tumors in rats at clinically relevant exposures. Whether it does so in people is unknown. The weekly products are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). Twice-daily Byetta carries no boxed warning.

Other contraindications are a prior serious allergic reaction to exenatide or the product’s ingredients, and a history of drug-induced immune thrombocytopenia from any exenatide product. The warnings section also covers:

• Low platelets from antibodies. Drug-induced immune thrombocytopenia can cause fatal bleeding. Because exenatide lingers for about 10 weeks after the last BCise dose, the label says the low platelets can persist that long.
• Acute pancreatitis, seen across the GLP-1 class.
• Hypoglycemia with a sulfonylurea or insulin; their doses may need lowering.
• Acute kidney injury from dehydration. BCise is not recommended when eGFR is below 45 mL/min/1.73 m² or in end-stage kidney disease.
• Severe stomach side effects. Not recommended in severe gastroparesis.
• Antibodies that blunt the glucose response, in which case another drug should be considered.
• Gallbladder disease: 1.9% on Bydureon versus 1.4% on placebo in EXSCEL.
• Aspiration under anesthesia or deep sedation, added to the label in November 2024.

The label also notes that exenatide can slow absorption of oral drugs and that INR can rise in people taking warfarin, so INR is checked more often when starting.

8. Was Bydureon discontinued?

Yes. The record, checked on November 8, 2026:

Drugs@FDA lists Bydureon (vial kit), the Bydureon Pen and Bydureon BCise as discontinued, and FDA’s drug shortage database shows extended-release exenatide with the status “Discontinuation.” No Bydureon product appeared in the FDA NDC Directory when checked. The insurer notice gave no reason for the US decision; the EMA record calls the EU withdrawal a commercial decision, not a safety action.

Twice-daily exenatide got a generic replacement from Amneal in 2025, although that generic was itself listed as discontinued by November 2026 (see Byetta). Weekly exenatide did not: the openFDA application records show no generic of the extended-release form.

9. Where does weekly exenatide still matter?

Mostly in research. The largest recent trial was in Parkinson’s disease, not diabetes. In the phase 3 Exenatide-PD3 trial, 194 people received extended-release exenatide 2 mg weekly or placebo for 96 weeks. Motor scores worsened 5.7 points on exenatide and 4.5 on placebo (P = 0.47), and the authors found no evidence that it slowed the disease. The exenatide page covers that trial and the earlier phase 2 signal.

For diabetes care, the weekly options that replaced Bydureon, such as Ozempic, Trulicity and Mounjaro, have their own trial records, and in SUSTAIN 3 semaglutide outperformed weekly exenatide on both glucose and weight. Choosing among them is a prescriber’s decision.

10. What should a log capture?

For anyone who used Bydureon or is reviewing past treatment, the label points to a few useful details: the injection day and site each week (nodules are common, so note any lump, redness or pain), missed or moved doses under the 3-day rule, HbA1c and weight at each check, and glucose readings if a sulfonylurea or insulin was also used. Unusual bruising or bleeding needs prompt medical attention because of the platelet risk.

The 10-week washout is the detail most often missed. A side effect, a glucose change or a weight change in the two months after the last injection may still reflect exenatide, which matters when a new drug is started in that window. A GLP-1 tracking log that records the date of the last Bydureon dose and the first dose of the next drug keeps that overlap visible.

11. Bydureon FAQ

• Is Bydureon BCise still available?

  No longer as a marketed product. A UnitedHealthcare notice dated December 19, 2024 says AstraZeneca discontinued Bydureon BCise on October 28, 2024. Drugs@FDA lists Bydureon, the Bydureon Pen and Bydureon BCise as discontinued, and no Bydureon product appeared in the FDA NDC Directory when checked on November 8, 2026. Unlike twice-daily Byetta, no generic version of weekly exenatide has been approved in the US.

• What is the difference between Bydureon and Bydureon BCise?

  Both deliver 2 mg of exenatide in slow-release microspheres once a week. The original Bydureon was sold as a vial kit and later the Bydureon Pen. BCise suspends the microspheres in a medium-chain triglyceride oil inside a single-dose autoinjector that is shaken and injected right away. BCise's current label also covers children 10 and older.

• Is Bydureon the same as Byetta?

  Same molecule, different release. Byetta is a plain exenatide solution with a 2.4-hour half-life, injected twice a day before meals. Bydureon releases exenatide over weeks, so it is injected once weekly regardless of meals, lowers HbA1c somewhat more, causes more injection-site nodules, and carries a thyroid boxed warning Byetta does not.

• Does Bydureon cause weight loss?

  Modestly. Weight fell about 1.4 to 2.3 kg in the label's 26- to 28-week trials, and 1.9 kg over 56 weeks in SUSTAIN 3, against 5.6 kg on semaglutide 1 mg. Bydureon was never approved for weight loss.

• Did Bydureon reduce heart attacks or strokes?

  Not significantly. In EXSCEL, major cardiovascular events occurred in 11.4% on exenatide and 12.2% on placebo over a median of 3.2 years, a hazard ratio of 0.91 (95% CI 0.83 to 1.00). That met the test for safety but missed superiority (P = 0.06), so Bydureon never gained a cardiovascular risk-reduction indication.

• Why do Bydureon injections cause lumps?

  The microspheres sit under the skin while they slowly break down and release the drug. In the BCise trials, nodules occurred in 10.5% of patients and any injection-site reaction in 23.9%. The label also lists rare serious reactions, including abscess, cellulitis and necrosis, some needing surgery.

• How long does Bydureon stay in the body?

  About 10 weeks. The label says plasma exenatide generally falls below the measurable level of 20 pg/mL around 10 weeks after the last dose, which matters for side effects, low platelets if they occur, and switching to another drug.

12. Sources